Ã±aco

Until 30 matches for your search Ã±aco can be filled in by people interested in the topic related to Ã±aco what are you interested in.

Aço Inox - brasil.aperam.com

Aperam South America AISI ASTM (UNS) DIN C Mn Si P S Cr Ni Mo N Outros Austeníticos 301 301 S30100 1.4310 0,15 2 1 0,045 0,03 16-18 6-8 –– 0,1 –– 301LN - D2.
From: brasil.aperam.com

Next Generation ACO Model - CMS Innovation Center

– A regional efficiency adjustment of ±1.0% – A national efficiency adjustment of ±0.5% The quality- and efficiency-adjusted discount for an NGACO thus can vary from -0.5 to -4.5% (assuming a +1.0% quality adjustment for an ACO’s first year in the Model, range is from -0.5 to ….
From: innovation.cms.gov

MassHealth’s New World of ACOs — and a Mighty Upstart ...

Apr 13, 2018 · [I wrote this commentary for the spring issue of Commonwealth Magazine. I am watching the new crop of 17 Accountable Care Organizations -- ACOs -- with great interest. This is a nationally important demonstration that also holds risks for the medical care of many MassHealth enrollees.] ON MARCH 1, the state’s Medicaid program—known as …[I wrote this commentary for the spring issue of Commonwealth Magazine. I am watching the new crop of 17 Accountable Care Organizations -- ACOs -- with great interest. This is a nationally important demonstration that also holds risks for the medical care of many MassHealth enrollees.] ON MARCH 1, the state’s Medicaid program—known as MassHealth—entered….
From: healthstew.com

[I wrote this commentary for the spring issue of Commonwealth Magazine. I am watching the new crop of 17 Accountable Care Organizations — ACOs — with great interest. This is a nationally important demonstration that also holds risks for the medical care of many MassHealth enrollees.]ON MARCH 1, the state’s Medicaid program—known as MassHealth—entered a new era with the launch of 17 accountable care organizations, or ACOs, aiming to provide better coordinated care at lower costs to its low-income enrollees. It’s an ambitious effort with lots of risk and big potential rewards. Within this is another compelling effort to redefine how community health centers fit into the changing health care landscape of Massachusetts and the nation. Christina Severin, CEO of C3, the new accountable care organization formed by community health centers.It began with a serendipitous encounter at a grocery store. Sometime in the fall of 2014, Christina Severin bumped into Lori Berry at the seafood counter of the Brighton Whole Foods market. Severin, a long-time leader in the MassHealth scene, had been mulling the creation of a community health center-based non-profit to join the cohort of ACOs being planned for as many as two-thirds of the 1.9 million Massachusetts residents who rely on the program.Severin had been a savvy player in Boston-area health care organizations for 20-plus years, at Codman Square Health Center in Dorchester, at the Medicaid managed care organization called Network Health, at Beth Israel Deaconess Hospital’s new ACO, and more. Berry, now retired, was the long-serving CEO of the Lynn Community Health Center. They agreed that, under the likely scenario, the state’s highly regarded community health center network would play second banana at best in the emerging, hospital-dominated MassHealth ACO sweepstakes. Severin floated an out-the-box idea: “Why don’t health centers start their own ACO?” Berry was intrigued.Manny Lopes, the energetic CEO of the East Boston Neighborhood Health Center, the state’s largest community health center, had the same idea and organized four other health center leaders, including Berry, to promote it. An early stop in 2015 took them to Marylou Sudders, Gov. Charlie Baker’s new secretary of health & human services and the key driver in the complex, high-stakes ACO deal with the US Centers for Medicare and Medicaid Services.At her first meeting with the rebels, Sudders and her MassHealth director, Daniel Tsai, expressed skepticism, worried that the earnest health center directors didn’t sufficiently grasp the concept of

See detail

ACO Series (Fixed Models) Kosho Inc.

Type ACO (SPXO oscillator, 7050 size, 4 pads) Power Suppliy Voltage Vdc +3.3V ±10% +5.0V ±10% Frequency Range 1.400 MHz to 70.000 MHz 71.000 MHz to 180.000 MHz 20.000 MHz to 60.000 MHz 61.000 MHz to 125.000 MHz Frequency Stability All Conditions ±20ppm to ±100ppm Operating Temperature-200 to +700 C-400 to +850 C Storage Temperature -400 to ....
From: www.morion-us.com

Th1D.4.pdf OFC 2017 © OSA 2017 Lessons Learned …

the [0, Baud-Rate] window on a port to port basis depending on the specific ACO that is plugged in. As currently defined in the CFP2-ACO OIF agreement [2], in its class 2/3 variants, the module should provide the host with an accurate, mask-compliant, S21 profile per lane. However, it has been our experience that many ACO vendors do not.
From: www.microsoft.com

FEATURES - Abracon

ACO Pb 20.2 x12.6 x 5.08 mm RoHS Compliant ABRACON IS CERTIFIED ISO9001:2008 2 Faraday, Suite# B | Irvine | CA 92618 Revised: 01.20.16 Ph. 949.546.8000 | Fax. 949.546.8001 LLC Visit www.abracon.com for Terms and Conditions of Sale FULL SIZE DIP LOW VOLTAGE 5.0V CRYSTAL CLOCK OSCILLATOR Moisture Sensitivity Level (MSL) – This product is ....
From: abracon.com

The Norma cluster (ACO 3627) - III. The distance and ...

Inhibition of the INa/K and the activation of peak INa ...

Aug 03, 2020 · ACO decreased the I Na/K by 26.8% ± 4.5% and 48.6% ± 14.6% at concentrations of 0.3 and 3 μM, respectively (Fig. 7g). A similar inhibitory effect of MACO on the I …Aconitine (ACO), a main active ingredient of Aconitum, is well-known for its cardiotoxicity. However, the mechanisms of toxic action of ACO remain unclear. In the current study, we investigated the cardiac effects of ACO and mesaconitine (MACO), a structurally related analog of ACO identified in Aconitum with undocumented cardiotoxicity in guinea pigs. We showed that intravenous administration of ACO or MACO (25 μg/kg) to guinea pigs caused various types of arrhythmias in electrocardiogram (ECG) recording, including ventricular premature beats (VPB), atrioventricular blockade (AVB), ventricular tachycardia (VT), and ventricular fibrillation (VF). MACO displayed more potent arrhythmogenic effect than ACO. We conducted whole-cell patch-clamp recording in isolated guinea pig ventricular myocytes, and observed that treatment with ACO (0.3, 3 μM) or MACO (0.1, 0.3 μM) depolarized the resting membrane potential (RMP) and reduced the action potential amplitude (APA) and durations (APDs) in a concentration-dependent manner. The ACO- and MACO-induced AP remodeling was largely abolished by an INa blocker tetrodotoxin (2 μM) and partly abolished by a specific Na+/K+ pump (NKP) blocker ouabain (0.1 μM). Furthermore, we observed that treatment with ACO or MACO attenuated NKP current (INa/K) and increased peak INa by accelerating the sodium channel activation with the EC50 of 8.36 ± 1.89 and 1.33 ± 0.16 μM, respectively. Incubation of ventricular myocytes with ACO or MACO concentration-dependently increased intracellular Na+ and Ca2+ concentrations. In conclusion, the current study demonstrates strong arrhythmogenic effects of ACO and MACO resulted from increasing the peak INa via accelerating sodium channel activation and inhibiting the INa/K. These results may help to improve our understanding of cardiotoxic mechanisms of ACO and MACO, and identify potential novel therapeutic targets for Aconitum poisoning..
From: www.nature.com

Chemicals and drugs
ACO, MACO, and amphotericin B were purchased from Sigma-Aldrich (St. Louis, MO, USA). They were prepared as stock solutions by dissolving in dimethylsulfoxide (DMSO) and diluting to the final concentration with external or internal solution before the start of the experiment. The final concentration of DMSO was less than 0.01%, which does not affect peak INa, INa/K, or APs. Tetrodotoxin (TTX, Sigma-Aldrich) was also prepared as a stock solution by dissolving it in distilled water and was stored at −80 °C. OUA (Sigma-Aldrich) was simply added to the external solution before the experiments. Type II collagenase was purchased from Worthington Biochem, Freehold, NJ, USA. Nimodipine and RIPA lysis buffer were purchased from Thermo Fisher Scientific, Rockford, IL, USA. Fluo-4 AM was purchased from Invitrogen, Carlsbad, CA, USA.
Animals
Male guinea pigs (Hartly, 300–350 g) were obtained from the Experimental Animal Center of Hebei Medical University. The uses of experimental animals were approved by the Institutional Animal Care and Use Committee of Hebei Medical University. This investigation conformed to the Guidelines for the Care and Use of Laboratory Animals and followed the approval of the Bioethical Committee of Hebei Medical University.
ECG recordings
The ECG recordings were performed on 25 male guinea pigs weighing 300–350 g. The animals were randomly assigned into three groups: the saline control group (n = 5, to reduce the number of animals used), the ACO group (25 μg/kg group, n = 10), and the MACO group (25 μg/kg group, n = 10). After weighing, the animals were anesthetized by intraperitoneal injection with 1.2% sodium pentobarbital at a dosage of 3 mL/kg [11]. After 10 min of stabilization, 25 μg/kg ACO or MACO was administered as a bolus injection through the femoral vein. The dosages of ACO and MACO were determined based on previous studies [4, 5] and our preliminary experiment. Normal saline solution (1.0 mL/kg) was given to the control animals. Next, the standard lead II ECGs were continuously recorded using a computerized Bipoc System (RM6240, Chengdu, China) for 120 min before and after the administration of ACO, MACO, or normal saline. Arrhythmias were evaluated according to the diagnostic criteria advocated by the Lambeth Convention [16]. After recordings, the time of the first occurrence (onset time) and the incidence (the rate of occurrence) of various arrhythmias in each group were analyzed. Finally, the time to death of each animal and mortality in each group were calculated.
Isolation of single ventricular myocytes
Single ventricular myocytes were enzymatically dissociated from the hearts of healthy adult guinea pigs (300–350 g)

See detail

CDC Newsroom - cdc.gov

VersiÃ³n en English; El estudio del Morbidity and Mortality Weekly Report. Los participantes en el estudio que indicaron que llamarÃan para pedir ayuda de emergencia, o que llamarÃan a personal mÃ©dico para reportar un ataque cardÃaco o un derrame, oscilaron entre el 78 por ciento en Mississippi y el 89 por ciento en Minnesota.Los hispanos tienen menos probabilidades de reconocer las seA±ales de aviso de un ataque cardAaco y tomar medidas apropiadas, revela un estudio de CDC.
Keyword: Los hispanos tienen menos probabilidades de reconocer las seÃ±ales de aviso de un ataque cardÃaco y tomar medidas apropiadas, revela un estudio de CDC
From: www.cdc.gov

Cavilha paralela com rosca interna endurecida DIN 7979 D ...

Looking for Cavilha paralela com rosca interna endurecida DIN 7979 D Aço 60±2HRC Sem tratamento de superficie? Fabory offers the best buy of Cavilhas paralelas Delivery within 48 hours Payment on invoice 100.000+ products in stockLooking for Cavilha paralela com rosca interna endurecida DIN 7979 D Aço 60±2HRC Sem tratamento de superficie? Fabory offers the best buy of Cavilhas paralelas ✓ Delivery within 48 hours ✓ Payment on invoice ✓ 100.000+ products in stock.
Keyword: din-7979d, din7979d, din_7979d, din+7979d, din 7979d, d7979d
From: www.fabory.com

[Using peripheral perfusion index and venous-to-arterial ...

However, the PI≤0.6 group had a significantly higher Pv-aCO(2) than other groups. Moreover, the patients with non-lactate clearance (13/32) had a higher Pv-aCO(2)/Ca-vO(2) ratio than the patients with lactate clearance in PI≥1.4 group (1.9±0.7 vs. 1.3±1.0, P=0.01).Objective: The relationship of venous-to-arterial CO(2) difference(Pv-aCO(2))/arterial-central venous O(2) difference (Ca-vO(2)) ratio, peripheral perfusion index(PI) and lactate clearance(LC) were investigated during resuscitation in septic patients. And, the meaning of the combination PI an ….
Keyword: pmid:30486561, doi:10.3760/cma.j.issn.0578-1426.2018.12.008, H W He, D W Liu, R Zhang, APACHE, Carbon Dioxide / blood*, Central Venous Pressure, Female, Hemodynamics, Hospitalization, Hospitals, Humans, Lactic Acid / blood*, Male, Mental Disorders, Middle Aged, Multivariate Analysis, Oxygen / blood*, Oxygen Consumption, Resuscitation, Risk Factors, Sepsis, Shock, Septic / blood*, PubMed Abstract, NIH, NLM, NCBI, National Institutes of Health, National Center for Biotechnology Information, National Library of Medicine, MEDLINE
From: pubmed.ncbi.nlm.nih.gov

ACO (Asthma–COPD Overlap) Is Independent from COPD, a Case ...

May 11, 2021 · FEV 1 54.1 ± 12.1% (COPD), 70.0 ± 13.8% (asthma), 55.8 ± 12.4% (ACO) Radiographical evidence of sinonasal inflammation (Lund-Mackay staging, LMS) In patients with ACO and COPD, total and ethmoid LMS scores were …Asthma and chronic obstructive pulmonary disease (COPD) are now recognized to be able to co-exist as asthma–COPD overlap (ACO). It is clinically relevant to evaluate whether patients with COPD concurrently have components of asthma in primary ....
From: www.ncbi.nlm.nih.gov

1.1. Background of Asthma and Chronic Obstructive Pulmonary Disesase
The global burdens of asthma and chronic obstructive pulmonary disease (COPD) are increasing, each of which was estimated to affect respectively approximate 339 million and 251 million people worldwide in 2016 [1]. It has been widely accepted that asthma and COPD are strikingly different airway disorders [2,3]. Although the “Dutch hypothesis” suggested a common genetic background underlying airway obstruction with a spectrum of clinical entities from asthma to COPD, recent genetic research indicated that it was unlikely that genetic factors are shared by asthma and COPD [4].Asthma is a heterogenous and inflammatory disease affecting large and small respiratory tracts but not the lung parenchyma, and contains clusters of demographical, clinical and pathophysiological characteristics underpinned by different pathophysiological processes [5]. This heterogeneity may be explained by the complexity of dysregulated innate and adaptive inflammatory responses to exogenous allergens and proteases leading to the spectrum of abnormal tissue remodeling, where type 2 cytokines such as interleukin (IL)-4, IL-13 and IL-5 primarily promote airway eosinophil infiltration, mucus hypersecretion, bronchial hyperresponsiveness and mast cell activation [6]. Major subpopulations of asthmatics have molecular signatures of T helper 2 (Th2)—inflammation and airway obstruction that markedly respond to inhaled corticosteroid (ICS) [7]. In line with this translational study, accumulated evidence from randomized control trials have revealed the importance of ICS usage from the early steps of asthma treatment because clinical studies have shown that ICS robustly reduced the risk of symptoms, exacerbations, hospitalization and mortality from asthma [8,9,10].COPD is defined as a common, preventable and treatable disease that is characterized by persistent respiratory symptoms and airflow limitation that is due to airway and/or alveolar abnormalities usually caused by significant exposure to noxious particles or gases and influenced by host factors including abnormal lung development [11]. In addition to cigarette smoking, known as the most common COPD risk factor [12], the susceptibility could be influenced by genetic factors [13,14] and abnormal lung growth [15]. Unlike asthma, CD4+ T helper 1 (Th1) cells, CD8+ cytotoxic T (Tc) cells, neutrophils and macrophages predominantly affect the small airways and the lung parenchyma leading to mucus hypersecretion, alveolar wall destruction (emphysema) and small airway fibrosis in COPD [2,16]. These pro-inflammatory cell-types are functionally altered by oxidative stress and intracellular signaling pathways including activation of the proinflammatory transcription factor nuclear factor κB (NF-κB) [17], and alveolar macrophages are defective in bacterial phagocytosis, possibly via several

See detail

A two-stage hybrid ant colony optimization for high ...

Aug 01, 2021 · Abstract. Ant colony optimization (ACO) is widely used in feature selection owing to its excellent global/local search capabilities and flexible graph representation. However, the current ACO-based feature selection methods are mainly applied to low-dimensional datasets. For thousands of dimensional datasets, the search for the optimal feature ...Ant colony optimization (ACO) is widely used in feature selection owing to its excellent global/local search capabilities and flexible graph represent….
From: www.sciencedirect.com

Metabolomic fingerprinting and systemic inflammatory ...

May 24, 2020 · In fact, the definition of ACO is still evolving, and different clinical definitions are being provided in various studies [5–8]. The prevalence of ACO depends on how it is defined, but it is relatively common in clinical practice, affecting 15 to 20% of patients with asthma and COPD .Asthma-COPD overlap (ACO) refers to a group of poorly studied and characterised patients reporting with disease presentations of both asthma and COPD, thereby making both diagnosis and treatment challenging for the clinicians. They exhibit a higher burden ....
From: www.ncbi.nlm.nih.gov

Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/The energy metabolites, cholesterol and fatty acids correlated significantly with the immunological mediators, suggesting existence of a possible link between the inflammatory status of these patients and impaired metabolism. The present findings could be possibly extended to better define the ACO diagnostic criteria, management and tailoring therapies exclusively for the disease.Eleven metabolites [serine, threonine, ethanolamine, glucose, cholesterol, 2-palmitoylglycerol, stearic acid, lactic acid, linoleic acid, D-mannose and succinic acid] were found to be significantly altered in ACO as compared with asthma and COPD. The levels and expression trends were successfully validated in a fresh cohort of subjects. Thirteen immunological mediators including TNFα, IL-1β, IL-17E, GM-CSF, IL-18, NGAL, IL-5, IL-10, MCP-1, YKL-40, IFN-γ, IL-6 and TGF-β showed distinct expression patterns in ACO. These markers and metabolites exhibited significant correlation with each other and also with lung function parameters.Global metabolomic profiling using two different groups of patients [discovery (D) and validation (V)] were conducted. Serum samples obtained from moderate and severe asthma [n = 34(D); n = 32(V)], moderate and severe COPD [n = 30(D); 32(V)], ACO patients [n = 35(D); 40(V)] and healthy controls [n = 33(D)] were characterized using gas chromatography mass spectrometry (GC-MS). Multiplexed analysis of 25 immunological markers (IFN-γ (interferon gamma), TNF-α (tumor necrosis factor alpha), IL-12p70 (interleukin 12p70), IL-2, IL-4, IL-5, IL-13, IL-10, IL-1α, IL-1β, TGF-β (transforming growth factor), IL-6, IL-17E, IL-21, IL-23, eotaxin, GM-CSF (granulocyte macrophage-colony stimulating factor), IFN-α (interferon alpha), IL-18, NGAL (neutrophil gelatinase-associated lipocalin), periostin, TSLP (thymic stromal lymphopoietin), MCP-1 (monocyte chemoattractant protein- 1), YKL-40 (chitinase 3 like 1) and IL-8) was also performed in the discovery cohort.Asthma-COPD overlap (ACO) refers to a group of poorly studied and characterised patients reporting with disease presentations of both asthma and

See detail

especificação de tubo de aço galvanizado, Tamanho da ...

Feb 14, 2019 · China tubo de aço galvanizado por imersão a quente padrão|especificação de tubo de aço galvanizado frio, tamanho peso teórico regulação tabela da grade OD mm Espessura da parede mm mínima da parede de tubos soldados ( 6 m de comprimento fixo) Tubulação galvanizada ( 6 m de comprimento fixo) Nominal inner diameter inch Thick mm Meter weight …tubulacao de aco de abter,sem costura e tubos de aco carbono,carcaca e tubo tubo.
From: www.abtersteel.com

Cavilha paralela temperada m6 DIN 6325 Aço 60±2HRC Sem ...

Looking for Cavilha paralela temperada m6 DIN 6325 Aço 60±2HRC Sem tratamento de superficie? Fabory offers the best buy of Cavilhas paralelas Delivery within 48 hours Payment on invoice 100.000+ products in stockLooking for Cavilha paralela temperada m6 DIN 6325 Aço 60±2HRC Sem tratamento de superficie? Fabory offers the best buy of Cavilhas paralelas ✓ Delivery within 48 hours ✓ Payment on invoice ✓ 100.000+ products in stock.
Keyword: din-6325, din 6325, din_6325, din+6325, d6325, din6325
From: www.fabory.com

Oleopator Bypass G - ACO Building Drainage

GA-2 is an alarm device for monitoring the thickness of the grease layer accumulating in a grease interceptor and the blocking of the interceptor. The system consists of a GA-2 control unit, two GA-SG1 sensors and a cable joint. Description. Dimensions 125 mm x 75 mm x 35 mm (L x H x D).
From: www.buildingdrainage.aco

Agenda Rural ACO

ACO -40 Depression Remission at Twelve Months ² ² ACO -27 Diabetes Mellitus: Hemoglobin A1c Poor Control 25.63% 12% ACO -41 Diabetes: Eye Exam 38.63% 34% ACO -28 Hypertension: Controlling High Blood Pressure 67.86% 76% ACO -30 Ischemic Vascular Disease: Use of Aspirin or Another Antithrombotic 80.88% 93%.
From: nebraskaruralhealth.org

Utility of FeNO in differentiating ACO and COPD | European ...

Result: 44% (n=60), FeNO based and 45% (n=61), criteria based are ACO patients. Majority (n=39) were in intermediate range (25-50ppb). Mean FeNO in ACO group and COPD was 40.13 ± 17.2ppb and 12.35 ± 4.19ppb (p<0.001) Using ROC curve, best cut off value for FeNO was obtained as 22ppb. 85%of patients had their FeNO values concordant with ...Introduction: ACO is a disease entity which warrants early screening and isolation from COPD for which FeNO is a useful tool, we are the first to attempt the same in Indian population Aim: To assess the contribution of FeNO in differentiating ACO from COPD in patients with persistent airflow limitation Objectives: 1) Assess FeNO levels in patients diagnosed as ACO on the basis of guidelines and compare with the levels in COPD;2) Assess if lung function parameters in ACO correlate with FeNO levels and;3) Compare FeNO levels of smokers and non smokers Material and methods: Prospective observational study, over a year in 136 patients attended OPD with COPD who were subjected to spirometry and FeNOmetry. According to ERS consensus based definition, patients were categorized as ACO and COPD. FeNO value of 22.5ppb as cut off was used for FeNO based categorisation Result: 44% (n=60), FeNO based and 45%(n=61), criteria based are ACO patients. Majority(n=39) were in intermediate range(25-50ppb). Mean FeNO in ACO group and COPD was 40.13 ± 17.2ppb and 12.35 ± 4.19ppb (p<0.001) Using ROC curve, best cut off value for FeNO was obtained as 22ppb 85%of patients had their FeNO values concordant with criteria defining ACO There was good agreement between criteria and FeNO based differentiation(κ=0.74 and p<0.001) Difference in mean FeNO value between smokers(22.91 ± 17.13 ppb) and non smokers(31.81 ± 20.96 ppb) was found to be statistically significant(p=0.024) Significant positive association (κ=0.32) between post-bronchodilator reversibility with FeNO values(p<0.01) Conclusion: FeNO can be used as a highly sensitive tool to differentiate ACO from COPD Abbreviation: ACO - Asthma COPD Overlap COPD - Chronic Obstructive Pulmonary Disease FeNO - Fractional Exhaled Nitric Oxide Footnotes Cite this article as: European Respiratory Journal 2019; 54: Suppl. 63, PA357. This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at [www.ers-education.org][1] (ERS member access only). [1]: http://www.ers-education.org.
From: erj.ersjournals.com

web.mit.edu

#%$'&)(+*-,.0/2143 5-365+7-, *-8 9;:=[email protected] :[email protected]>almf>afonqphgsrtf lmbclmus: v wklm:=fowx:=y z>[ycyk>swe\6] yc:=bebcy ^_f yebclmbc] be: gai-`-:awe\ f ....
From: web.mit.edu

Differential DAMP release was observed in the sputum of ...

Dec 17, 2019 · The sputum levels of LL-37 were elevated in the COPD and ACO groups (78.16 ± 7.77 and 46.03 ± 6.16 ng/mL, respectively) but decreased in the asthma group compared to the HS group (29.82 ...Asthma-COPD overlap (ACO) has been under intensive focus; however, the levels of damage-associated molecular patterns (DAMPs) that can activate the innate and adaptive immune responses of ACO are unknown. The present study aimed to examine the levels of some DAMPs in asthma, COPD, and ACO and to identify the associations between clinical characteristics and DAMPs in ACO. Sputum from subjects with asthma (n = 87) or COPD (n = 73) and ACO (n = 68) or from smokers (n = 62) and never-smokers (n = 62) was analyzed for high mobility group protein B1 (HMGB1), heat shock protein 70 (HSP70), LL-37, S100A8, and galectin-3 (Gal-3). The concentration of HMGB1, HSP70, LL-37, and S100A8 proteins in sputum from ACO patients was significantly elevated, whereas that of Gal-3 was reduced, compared to that of smokers and never-smokers. The levels of HMGB1 and Gal-3 proteins in ACO patients were elevated compared to those in asthma patients. The sputum from ACO patients showed an increase in the levels of LL-37 and S100A8 proteins compared to that of asthma patients, whereas the levels decreased compared to those of COPD patients. The concentrations of HMGB1, HSP70, LL-37, and S100A8 proteins in the sputum of 352 participants were negatively correlated, whereas the levels of Gal-3 were positively correlated, with FEV1, FEV1%pred, and FEV1/FVC. Sputum HMGB1 had a high AUC of the ROC curve while distinguishing ACO patients from asthma patients. Meanwhile, sputum LL-37 had a high AUC of the ROC curve in differentiating asthma and COPD. The release of sputum DAMPs in ACO may be involved in chronic airway inflammation in ACO; the sputum HMGB1 level might serve as a valuable biomarker for distinguishing ACO from asthma, and the sputum LL-37 level might be a biomarker for differentiating asthma and COPD..
From: www.nature.com

Recently, ACO has been under intensive research. Although several studies have focused on the symptoms and clinical characteristics of ACO, the pathophysiology of this disease has been poorly investigated. In the present study, the levels of sputum HMGB1, HSP70, S100A8, and LL-37 were elevated, while those of sputum Gal-3 were decreased, in patients with ACO compared to healthy controls. Interestingly, the distinct release of these DAMPs between ACO and asthma or COPD indicated that the specific pathophysiology of ACO might differ from that of asthma and COPD. Moreover, sputum HMGB1 may serve as a biomarker for the differentiation of ACO patients from NS, HS, and asthma patients, while sputum LL-37 may differentiate asthmatics from those with COPD. Finally, consistent with previous studies8,9,11, we found that the levels of these DAMP molecules in the asthma, COPD and ACO patients were significantly different from those in the normal control groups in our study, indicating the important role of DAMPs in the pathogenesis of COPD.Although an accurate prevalence of ACO was not detected, 13–73% of all COPD patients and 2% of severe asthmatics fulfilled the criteria for ACO11,16. In this study, 29.8% of patients with ACO were similar to that demonstrated previously16. In addition, the study17 demonstrated that the patients with ACO had a lower lung function parameter, while those in our study had lower smoking pack-years and higher FEV1 and FEV1/FVC% compared to the COPD patients.The role of DAMPs in the pathophysiology of COPD has been reviewed and discussed by Pouwels et al.8. Reportedly, HMGB1 levels were elevated in patients with asthma and COPD and independently correlated with the pulmonary function parameters9. In a previous study, we also demonstrated that treatment with anti-HMGB1 antibody significantly reversed the development of airway remodeling in a murine asthma model18. The elevated levels of HMGB1 in ACO suggested its role in the pathogenesis of ACO as well as asthma and COPD. Moreover, the interaction of HMGB1 with TLR-2, -4, -9, and RAGE can promote the activation of neutrophils, macrophages, and dendritic cells, followed by the release of inflammation mediators19. In addition, the sputum HMGB1 levels in the ACO group were negatively correlated with the FEV1%, indicating that HMGB1 in induced sputum may be a useful biomarker for the disease severity of ACO. Strikingly, the current study stated that sputum HMGB1 had a high sensitivity and specificity in distinguishing ACO from NS, HS, and asthma patients and

See detail

gBeam-ACO: a greedy and faster variant of Beam-ACO | DeepAI

Apr 23, 2020 · gBeam-ACO: a greedy and faster variant of Beam-ACO. Beam-ACO, a modification of the traditional Ant Colony Optimization (ACO) algorithms that incorporates a modified beam search, is one of the most effective ACO algorithms for solving the Traveling Salesman Problem (TSP). Although adding beam search to the ACO heuristic search process is ...04/23/20 - Beam-ACO, a modification of the traditional Ant Colony Optimization (ACO) algorithms that incorporates a modified beam search, is ....
From: deepai.org

Short-term effects of atropine combined with ...

Jun 01, 2021 · 1. Introduction. The increasing prevalence of myopia has given rise to a heavy burden on society globally, especially in East Asia [, , ].Holden et al. [] estimated that there will be up to 1 billion people (1/5 of the world's population) with high myopia by 2050 without interventions for myopia control.The biological basis of myopia progression is usually …To analyse the one-month change in subfoveal choroidal thickness (SFChT) of myopic children treated with 0.01 % atropine, orthokeratology (OK), or the….
From: www.sciencedirect.com

cma.org.sa

>' ±' =D qG1_*E ?1¢1'2 A'1'u A'a, ¤cG/ {3c D_{[email protected]{4 ﺔﻴﻄﻐﺘﻟا ﺪﻬﻌﺘﻣ ﺪﻋﺎﺴﻣ ﺲﻴﺋﺮﻟا ﺔﻴﻄﻐﺘﻟا ﺪﻬﻌﺘﻣ بﺎﺘﺘﻛﻻا ﺮﻳﺪﻣو ﻲﻟﺎﻤﻟا رﺎﺸﺘﺴﻤﻟا.
From: cma.org.sa

Clinical characteristics of patients with asthma COPD ...

Results: Pre-bronchodilator Forced Expiratory Volume in 1 second (mean±SD 58.4±14.3 vs 67.5±20.1% predicted) and Forced Vital Capacity (mean 82.1±16.9 v 91.9±17.2% predicted) were significantly lower in the ACO group (p<0.001), but no difference was ….
From: research.monash.edu

Short-term effects of atropine combined with ...

Purpose: To analyse the one-month change in subfoveal choroidal thickness (SFChT) of myopic children treated with 0.01 % atropine, orthokeratology (OK), or their combination. Methods: This is a prospective, randomized controlled trial. One hundred fifty-four children aged between 8 and 12 years with a spherical equivalent (SE) of -1.00 to -6.00 diopters were enrolled.The combination of OK and atropine induced a greater increase in SFChT than monotherapy with atropine, which might indicate a better treatment effect for childhood myopia control..
Keyword: pmid:32620344, doi:10.1016/j.clae.2020.06.006, Randomized Controlled Trial, Wenchen Zhao, Zhouyue Li, Xiao Yang, Atropine*, Axial Length, Eye / diagnostic imaging, Child, Humans, Orthokeratologic Procedures*, Prospective Studies, Refraction, Ocular, PubMed Abstract, NIH, NLM, NCBI, National Institutes of Health, National Center for Biotechnology Information, National Library of Medicine, MEDLINE
From: pubmed.ncbi.nlm.nih.gov

Purpose:

To analyse the one-month change in subfoveal choroidal thickness (SFChT) of myopic children treated with 0.01 % atropine, orthokeratology (OK), or their combination.

Methods:

This is a prospective, randomized controlled trial. One hundred fifty-four children aged between 8 and 12 years with a spherical equivalent (SE) of -1.00 to -6.00 diopters were enrolled. Subjects were randomly assigned to receive 0.01 % atropine and orthokeratology (ACO, n = 39), 0.01 % atropine and single vision glasses (atropine, n = 42), orthokeratology and placebo (OK, n = 36), or placebo and single vision glasses (control, n = 37). SFChT was assessed using optical coherence tomography (OCT). Ocular parameters, including axial length (AL), were measured using a Lenstar LS 900.

Results:

SFChT significantly increased in the ACO (14.12 ± 12.88 μm, p < 0.001), OK (9.43 ± 9.14 μm, p < 0.001) and atropine (5.49 ± 9.38 μm, p < 0.001) groups, while it significantly decreased in the control group (-4.81 ± 9.93 μm, p = 0.006). The one-month change in SFChT was significantly different between the control and treatment groups (p < 0.001). The results of pairwise comparisons among the treatment groups showed that the magnitude of the SFChT change was larger in the ACO group than in the atropine group (p = 0.002). The changes in the ACO and OK groups were not significantly different (p = 0.326).

Conclusion:

See detail

A Multiple Pheromone Table Based Ant Colony Optimization ...

May 17, 2015 · Ant colony optimization (ACO) is an efficient heuristic algorithm for combinatorial optimization problems, such as clustering. Because the search strategy of ACO is similar to those of other well-known heuristics, the probability of searching particular regions will be increased if better results are found and kept. Although this kind of search strategy may find a better …Ant colony optimization (ACO) is an efficient heuristic algorithm for combinatorial optimization problems, such as clustering. Because the search strategy of ACO is similar to those of other well-known heuristics, the probability of searching particular regions will be increased if better results are found and kept. Although this kind of search strategy may find a better approximate solution, it also has a high probability of losing the potential search directions. To prevent the ACO from losing too many potential search directions at the early iterations, a novel pheromone updating strategy is presented in this paper. In addition to the “original” pheromone table used to keep track of the promising information, a second pheromone table is added to the proposed algorithm to keep track of the unpromising information so as to increase the probability of searching directions worse than the current solutions. Several well-known clustering datasets are used to evaluate the performance of the proposed method in this paper. The experimental results show that the proposed method can provide better results than ACO and other clustering algorithms in terms of quality..
From: www.hindawi.com

The Norma cluster (ACO 3627) - III. The distance and ...

While Norma (ACO 3627) is the richest cluster in the Great Attractor (GA) region, its role in the local dynamics is poorly understood. The Norma cluster has a mean redshift (z CMB ) of 0.0165 and has been proposed as the `core' of the GA. We have used the K s -band Fundamental Plane (FP) to measure Norma cluster's distance with respect to the Coma cluster.While Norma (ACO 3627) is the richest cluster in the Great Attractor (GA) region, its role in the local dynamics is poorly understood. The Norma cluster has a mean redshift (z_CMB) of 0.0165 and has been proposed as the `core' of the GA. We have used the K_s-band Fundamental Plane (FP) to measure Norma cluster's distance with respect to the Coma cluster. We report FP photometry parameters (effective radii and surface brightnesses), derived from ESO New Technology Telescope Son of ISAAC images, and velocity dispersions, from Anglo-Australian Telescope 2dF spectroscopy, for 31 early-type galaxies in the cluster. For the Coma cluster we use Two Micron All Sky Survey images and Sloan Digital Sky Survey velocity dispersion measurements for 121 early-type galaxies to generate the calibrating FP data set. For the combined Norma-Coma sample we measure FP coefficients of a = 1.465 ± 0.059 and b = 0.326 ± 0.020. We find an rms scatter, in log σ, of ∼0.08 dex which corresponds to a distance uncertainty of ∼28 per cent per galaxy. The zero-point offset between Norma's and Coma's FPs is 0.154 ± 0.014 dex. Assuming that the Coma cluster is at rest with respect to the cosmic microwave background frame and z_CMB(Coma) = 0.0240, we derive a distance to the Norma cluster of 5026 ± 160 km s^-1, and the derived peculiar velocity is -72 ± 170 km s^-1, i.e. consistent with zero. This is lower than previously reported positive peculiar velocities for clusters/groups/galaxies in the GA region and hence the Norma cluster may indeed represent the GA's `core'..
From: ui.adsabs.harvard.edu

Advanced technology development reducing CO emissions

6 ACO Technology The basic materials of the chemical industry such as ethylene and propylene are being produced in the steam cracking process.4 One of the fastest growing petrochemical markets is that for propylene, driven primarily by the high growth rate of polypropylene.5 Therefore, various propylene technologies are investigated such as propane dehydrogenation, ….
From: www.osti.gov

BER performance of ACO-OFDM in AWGN, simulation (solid ...

This can be illustrated by Fig. 3b. Following the analysis in [24,26,44, 45], this section investigates the optimum ACO-OFDM power to mitigate clipping noise introduced by the PWM-like envelope ....
From: researchgate.net